Novo’s Ozempic Shows Promise in Reducing Dementia Risk
Recent findings from a study conducted by the University of Oxford suggest that Novo Nordisk’s popular diabetes drug, Ozempic (semaglutide), may also be effective in lowering the risk of dementia. This revelation could potentially pave the way for new treatment strategies for Alzheimer’s disease and other forms of cognitive decline. Key Findings of the Study…